Archive | November, 2019

NEW! RESI Launches Featured Company Pitch Session

21 Nov

By Gregory Mannix, Vice President International Business Development, LSN

Are you looking to raise a private financing round or find a strategic partner for your life science startup?  The 27th Redefining Early Stage Investments (RESI) Partnering Conference is offering an opportunity to present your firm at our San Francisco event taking place on January 14th, 2020 event taking place at the Marines’ Memorial Club and Hotel near Union Square. We expect 500+ early stage investors to attend RESI San Francisco 2020, making this a unique opportunity to get your company’s message out.

Featured Pitch Sessions

Early Stage firms seeking licensing deals or Seed, Angel, Series A or B funding can secure a 15-minute presentation slot at the upcoming RESI Partnering Conference.  With RESI’s focused audience of life science investors, and a 1:1 ratio of investors to startups, presenting at RESI is a unique opportunity to get in front of early stage partners. RESI will host over 500 global early stage investors ranging from family offices and angels to strategic Pharma and MedTech players. Presenting at RESI gives companies an opportunity to build their profile.

If your firm is interested in presenting in the Early Stage Company Pitch Sessions please click below.  You will be required to submit a two-page executive summary and 10-12 page pitch deck with your application.

Deadline for applications December 12th 2019.

Fee structure

  • RESI registration fee per attendee (register here)
  • Presentation fee per company:  $1,500 

Who should present?

Any life science company that is developing products in the Drugs, Devices, Diagnostics or Digital Health arena and is seeking licensing or investment.

Presentation Details:

  • Early Stage companies are invited to request a 15-minute company presentation.
  • Presenting companies will be featured in the LSN Newsletter, RESI website and in the RESI conference program guide.

What about the RESI Innovation Challenge?

Those who are familiar with RESI know of the RESI Innovation Challenge, a competition for companies on the day of the conference, where they present posters in the exhibit hall and compete for ‘investments’ of ‘RESI Cash’ from attendees, with the most successful winning prizes at the end of the day. The RESI Innovation Challenge is unique in that it involves a rigorous merit-based selection process that assesses the ‘investability’ of a company based on the innovativeness of their technology, the stage of development and potential market size, to name a few of the many criteria. The Innovation Challenge has always been extremely selective, with many more applying than are accepted to participate. Participation in the Innovation Challenge for selected companies is at no extra cost, to ensure that the selective nature of the Innovation Challenge remains solely merit based (apply here). However, we have found that a large number of companies would like the opportunity to present their companies to the broad audience in attendance at RESI. To accommodate them, we are launching the RESI Featured Company Pitch Sessions.

RESI San Francisco 2020 – Agenda Announced

21 Nov

By Lucy Parkinson, VP of Investor Research, LSN

On January 14th, RESI will be back in San Francisco, and LSN would like to present the panel and workshop agenda.  In addition to the all-new RESI Featured Company Pitch Sessions, RESI SF will feature three tracks of panel and workshop content, and RESI’s industry-leading Partnering from 8am-5pm.

RESI panels feature a moderator and 4 panelists who are experienced investors and industry experts who can guide entrepreneurs on what they need to do to raise capital.  RESI will feature panels focused on specific verticals, such as Early Stage Therapeutics, AI in Healthcare, Oncology Innovation, and an all-new panel on Investing In Life Science Tools.  Other panels focus on key investor groups such as Big Pharma, Corporate Venture Capital, Impact Investors, and Family Offices & Angels.  Additionally, RESI will include a half-day Asia Investors Track from 1.00-5.00pm, in which investors based in the Asia-Pacific region share their strategies on investing in global technology.

RESI’s workshops will include expert presentations on key issues for early stage entrepreneurs, including Company Valuation for Fundraising from Venture Valuation, and Negotiating Term Sheets from McDermott, Will & Emery, and an advice session from experts from the National Institutes of Health.

We hope you can join us during the San Francisco healthcare conference week to take part in this jam-packed agenda.

Life Science Nation’s, Focus on Cures Accelerator (FOC), Now Offering a Fundraising Campaign Curriculum

21 Nov

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN recently launched the Focus on Cures (FOC) Accelerator that helps high-growth, international startup companies move into the global partnering arena through a two-week Boston-based immersion program, titled MKT 466: Funding and Partnering Immersion Course, integrated into LSN’s global partnering network and the RESI conference series. The theme of the FOC accelerator is to create a funnel of elite, top domestic and foreign startups that need to raise angel, seed, series A and B rounds. This course solves an early stage funding challenge: there is no standardized methodology for teaching a company how to brand and message itself and efficiently manage a fundraising campaign. There is no reliable, accurate, and current partner and investor database (besides LSN’s) to get a company a list of global partners that are a fit for their stage of development and product set. Very few entrepreneurs are actually taught how to launch and manage a fundraising campaign, never mind training CEOs how to make an introductory phone call or write an introductory email. Most importantly, no one teaches the holy grail of canvassing for capital, which is, how to follow up.

Participants in the course receive:

  • A year subscription to the LSN investor database, valued at $6,995
  • Branding and messaging collateral for fund raising campaign, (including a logo, tagline, one page data sheet, two page executive summary, and 10-12 slide pitch), valued at $15K
  • A ticket to the next RESI conference to launch the fundraising campaign, valued at $3,000

The course is $10,000 per company, for services valued at $25,000, held at the LSN corporate headquarters in Downtown Crossing, Boston. Each company is expected to send one business and one science executive for the two week immersion class. The first class will be held from May 25th through Jun 5th, leading up to RESI San Diego, taking place on Monday, June 8th.

FOC Accelerator – MKT 466 Funding and Partnering Immersion Course

MKT466 is a unique two-week immersion course designed for life science entrepreneurs to experience the best methodologies for reaching out and establishing a dialogue with partners and  investors, building a relationship and, ultimately, securing capital allocations.

The morning sessions are 3-hour classes teaching the fundamental business development and marketing skills needed to formulate a company theme, create a corporate brand with appropriate messaging and market your firm to investors and strategic partners within the life science arena. (See details in the morning class outline)

The afternoon sessions include 1 hour of meeting the players in the Massachusetts life science ecosystem and 2 hours of curating and reaching out to a list of global investors and channel partners:

  1. Utilize LSN’s Company Database to build a full picture of global landscape of competitors
  2. Utilize LSN’s Investor Database to find investors and partners that are a fit for your stage of development and product set and aggregate a global target list
  3. Refine investor-centric marketing collateral (following the instructions of the Branding and Messaging class)
  4. Leverage your infrastructure to do email marketing campaigns and nurture leads in a CRM
  5. Start email and phone canvassing each day, supervised and mentored by LSN expert BD staff
  6. Set up intro phone calls and meetings
  7. Prepare for the upcoming RESI conference

Hot Investor Mandate: Family Office Investment Vehicle Seeks Early-Stage Therapeutic Opportunities with Strong Focus on Rare Disease

21 Nov

A family-run investment and commercialization vehicle invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs.

The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also considered attractive.

The firm has a strong preference for experienced management teams with proven tracks records of driving value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan-Based VC Firm Actively Seeks Cross Border Investment Opportunities in Medical Devices with Large Market Potential

21 Nov

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a USD 100 million fund. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia Based PE/VC Firm with Evergreen Fund Invests Up to $15M in Global Breakthrough Life Science Companies

21 Nov

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm with US and Canada Operations Invests in Early-Stage Medical Devices and Diagnostics Companies Globally

21 Nov

A venture capital firm with offices in USA and Canada is making investments out of its vintage 2017, fourth fund and is exclusively focused on supporting entrepreneurs commercializing advanced materials and advanced material process innovations within four verticals: energy, electronics, health, and sustainability. The firm typically makes initial investments in the $1M-$4M range and up to $8M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. The firm has strategic LP relationships in Asia, Europe, the Middle East, and North America and invests globally.

Within healthcare, the firm is interested in medical devices and diagnostics whose underlying technology is enabled by advanced materials or advanced material process innovations. The firm has a particular interest in 3D bioprinting, diagnostics and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing a disruptive 3D bioprinting platform, and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Newer Entries →